On Friday, Carisma Therapeutics Inc (NASDAQ: CARM) opened lower -5.70% from the last session, before settling in for the closing price of $0.23. Price fluctuations for CARM have ranged from $0.14 to $1.27 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 42.71% annually for the last half of the decade. Company’s average yearly earnings per share was noted 52.74% at the time writing. With a float of $21.80 million, this company’s outstanding shares have now reached $41.79 million.
Carisma Therapeutics Inc (CARM) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Carisma Therapeutics Inc is 47.84%, while institutional ownership is 4.29%.
Carisma Therapeutics Inc (CARM) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.31 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.36) by 0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 52.74% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 32.95% during the next five years compared to 42.71% growth over the previous five years of trading.
Carisma Therapeutics Inc (NASDAQ: CARM) Trading Performance Indicators
Check out the current performance indicators for Carisma Therapeutics Inc (CARM). In the past quarter, the stock posted a quick ratio of 0.48. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.83.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.18, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.52 in one year’s time.
Technical Analysis of Carisma Therapeutics Inc (CARM)
Let’s dig in a bit further. During the last 5-days, its volume was 18.74 million. That was better than the volume of 6.16 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 13.67%.
During the past 100 days, Carisma Therapeutics Inc’s (CARM) raw stochastic average was set at 6.50%, which indicates a significant increase from 4.97% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0259 in the past 14 days, which was lower than the 0.0416 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3415, while its 200-day Moving Average is $0.4078. However, in the short run, Carisma Therapeutics Inc’s stock first resistance to watch stands at $0.2285. Second resistance stands at $0.2421. The third major resistance level sits at $0.2510. If the price goes on to break the first support level at $0.2060, it is likely to go to the next support level at $0.1971. Assuming the price breaks the second support level, the third support level stands at $0.1835.
Carisma Therapeutics Inc (NASDAQ: CARM) Key Stats
There are currently 41,788K shares outstanding in the company with a market cap of 8.98 million. Presently, the company’s annual sales total 19,630 K according to its annual income of -60,480 K. Last quarter, the company’s sales amounted to 3,730 K and its income totaled -9,270 K.
